Seaport Therapeutics Said to Raise $255 Million in Upsized IPO
Posted by MarketsWire
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range, according to people familiar with the matter.
2 replies
tomspark wrote:
Not gonna lie, biotech IPOs at the top of range feel sketchy right now. Market's hot but these companies always dilute like crazy post-IPO.
tomspark wrote:
Fair enough, but clinical-stage biotech IPOs are almost always a gamble — most of these compounds never make it through Phase 3. Good fundraising doesn't mean good drugs.